Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Rheumatol. 2006 Nov;18(6):647-53.

Statin myopathy: an update.

Author information

  • 1Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA. LChrist4@jhmi.edu

Abstract

PURPOSE OF REVIEW:

Statin therapy has become the mainstay of treatment for lipid lowering, demonstrating cardiovascular risk reduction. Associated with statin popularity are misconceptions and fears of untoward side effects on muscle. This review clarifies the terminology relating to statin-related muscle disease; explores potential pathogenic mechanisms; reviews current estimates of statin myopathy prevalence; and examines diagnosis and management.

RECENT FINDINGS:

The fundamental mechanism of statin myopathy remains elusive but is believed to be a class effect. The most common explanation for the cause of toxic muscle injury invokes the deficiency of one of three main synthetic products in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway. Recent studies have revealed several patients with statin-induced rhabdomyolysis who also have metabolic muscle defects, indicating that statin use may unmask presymptomatic metabolic myopathies. Although statin-related myotoxicity is believed to be a noninflammatory, toxic myopathy, experimental evidence suggests that it may be triggered by an autoimmune reaction or, conversely, initiate an autoimmune process. The precise mechanism is uncertain.

SUMMARY:

As a class, statins appear to be usually safe, well tolerated agents with an excellent risk: benefit profile. The etiology and pathogenesis of statin myopathy are poorly understood owing to the relative rarity of its existence.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk